Aim: 

The purpose of the study was to follow the manner in which sulfizol influences the arterial pulmonary pressure and reactive oxygen species (ROS) production.

Methods: 

Our study was performed on a group of patients, which were diagnosed with arterial pulmonary hypertension using the echocardiographic method. The patients were divided in 2 groups: one group, which received sulfizol administrated orally for 3 days, 3x1g/day and another group, which was not treated with sulfizol. There are researches sustaining that sulfizol blocks the ET1 receptors. Before and after the treatment, all the patients were echocardiographically examined and simultaneously blood sampled and malondialdehyde (MDA), carbonylated proteins (CP) and ceruloplasmin concentrations in serum assessed.

Results: 

There are no significant changes of the parameters echocardiographically measured in both group of patients, before and after the treatment. The patients, compared with the reference group of healthy subjects, have considerably increased concentrations of MDA and CP (p < 0.001), thus demonstrating the presence of the oxidative stress in patients. After 3 days of treatment, the MDA and CP concentrations reduce no significantly at both groups of patients (p > 0.1). The same situation is noticed regarding ceruloplasmin levels before and after the treatment.

Conclusions: 

The arterial pulmonary hypertension is associated with a marked oxidative stress demonstrated by elevated values of MDA and CP. A 3 days treatment with sulfizol argues for a possible action of this drug on endothelin receptors.